title: Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.
abstract: A 40-year-old Caucasian female was first seen 20 years ago for a routine ocular screening in relation to hydroxychloroquine treatment for systemic lupus erythematosus. Her daily dose was 600 mg (or 12 mg/kg of body weight/day) of hydroxychloroquine. Three years later, she complained of mild visual loss in the right eye. Her best-corrected visual acuity was 0.9 in the right (RE) and 1.0 in the left eye (LE). In addition, she had a central scotoma (RE > LE) on automated visual field analysis (Humphrey central 30 degrees ). On fundoscopy and fluorescein angiography, the first signs of a bilateral bull's eye maculopathy were detected. A decreased Arden ratio on EOG (<1.50) was found with an accompanying decreased amplitude of the scotopic b-wave on full-field electroretinography in both eyes. Consequently, the treatment was immediately stopped. During the following years, the patient was retested regularly. After more than 18 years after cessation of the drug, most tests showed a further deterioration, including best-corrected visual acuity (RE: 0.1; LE: 0.7). On visual field testing, a progressive evolution to a total and absolute central scotoma in the RE (central 10 degrees ) and an annular scotoma in the LE became apparent. In contrast, a partial recovery of the Arden ratio of the EOG to 1.8 in both eyes was seen. In addition, a partial recovery of the scotopic b-wave full-field ERG was noted 19 years after cessation of treatment. At retest visits respectively 18, 19 and 20 years after cessation of hydroxychloroquine, a multifocal electroretinogram was performed in combination with colour vision tests and contrast sensitivity measurements.
authors.affiliation: Department of Ophthalmology, Universitair Ziekenhuis-Vrij Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium. paul.salu@uzbrussel.be
authors.forename: Paul
authors.initials: P
authors.lastname: Salu
authors.forename: André
authors.initials: A
authors.lastname: Uvijls
authors.forename: Pierre
authors.initials: P
authors.lastname: van den Brande
authors.forename: Bart P
authors.initials: BP
authors.lastname: Leroy
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015350:Contrast Sensitivity / Q000502:physiology; D018450:Disease Progression; D004596:Electroretinography; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects* / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008875:Middle Aged; D012160:Retina / Q000187:drug effects / Q000503:physiopathology*; D012164:Retinal Diseases / Q000139:chemically induced* / Q000503:physiopathology*; D012607:Scotoma / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
chemical_list: D018501:Antirheumatic Agents; D006886:Hydroxychloroquine
references.citation: Am J Med. 1988 Oct 14;85(4A):23-9
references.pmid: 3177429
references.citation: Doc Ophthalmol. 2006 May;112(3):177-87
references.pmid: 16804707
references.citation: Ophthalmology. 2002 Jul;109(7):1377-82
references.pmid: 12093666
references.citation: Am J Ophthalmol. 2005 Nov;140(5):794-807
references.pmid: 16310457
references.citation: Ophthalmologica. 1969;158 Suppl:592-604
references.pmid: 5307973
references.citation: Chang Gung Med J. 2001 May;24(5):329-34
references.pmid: 11480331
references.citation: Mem Acad R Med Belg. 1964;18:35-327
references.pmid: 14218315
references.citation: Graefes Arch Clin Exp Ophthalmol. 2000 Jan;238(1):94-7
references.pmid: 10664060
references.citation: Ann Ocul (Paris). 1957 Oct;190(10):713-46 contd
references.pmid: 13498490
references.citation: AMA Arch Ophthalmol. 1957 Mar;57(3):451-3
references.pmid: 13410231
references.citation: Ophthalmology. 1999 Sep;106(9):1799-803; discussion 1804
references.pmid: 10485553
references.citation: Eye (Lond). 1989;3 ( Pt 6):777-82
references.pmid: 2630362
references.citation: Doc Ophthalmol. 2009 Feb;118(1):29-36
references.pmid: 18465156
references.citation: Doc Ophthalmol. 2006 Nov;113(3):205-12
references.pmid: 17109157
references.citation: Am J Ophthalmol. 1979 Jul;88(1):1-11
references.pmid: 463998
references.citation: Doc Ophthalmol. 2009 Feb;118(1):69-77
references.pmid: 19030905
references.citation: Am J Med. 1983 Jul 18;75(1A):40-5
references.pmid: 6869410
references.citation: Lancet. 1959 Oct 3;2(7101):478-80
references.pmid: 14402143
references.citation: Doc Ophthalmol. 2005 Jan;110(1):111-20
references.pmid: 16249962
references.citation: Doc Ophthalmol. 2007 Sep;115(2):117-9
references.pmid: 17562091
references.citation: Am J Ophthalmol. 2001 Jun;131(6):761-6
references.pmid: 11384574
references.citation: Curr Eye Res. 2004 Apr;28(4):277-84
references.pmid: 15259297
references.citation: Am J Ophthalmol. 1967 Aug;64(2):245-52
references.pmid: 6036279
references.citation: Can J Ophthalmol. 1992 Aug;27(5):237-9
references.pmid: 1393809
references.citation: Arch Ophthalmol. 1964 Feb;71:157-65
references.pmid: 14089382
references.citation: Br J Ophthalmol. 2003 Jul;87(7):902-8
references.pmid: 12812896
references.citation: Am J Ophthalmol. 2007 May;143(5):801-809
references.pmid: 17336914
references.citation: Acta Ophthalmol (Copenh). 1967;:Suppl 92:1-71
references.pmid: 4866642
references.citation: Doc Ophthalmol. 2008 Jan;116(1):1-11
references.pmid: 17972125